229 related articles for article (PubMed ID: 22508299)
1. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Liao CH; Ko WC; Lu JJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.
Lin YC; Huang YT; Tsai PJ; Lee TF; Lee NY; Liao CH; Lin SY; Ko WC; Hsueh PR
Antimicrob Agents Chemother; 2011 Apr; 55(4):1701-5. PubMed ID: 21263053
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Yang JC; Lee PI; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
[TBL] [Abstract][Full Text] [Related]
4. Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019-2021.
Tsai CS; Lu PL; Lu MC; Hsieh TC; Chen WT; Wang JT; Ko WC
J Microbiol Immunol Infect; 2024 Apr; 57(2):320-327. PubMed ID: 38135646
[TBL] [Abstract][Full Text] [Related]
5. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
[TBL] [Abstract][Full Text] [Related]
7. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Saxton K; Baines SD; Freeman J; O'Connor R; Wilcox MH
Antimicrob Agents Chemother; 2009 Feb; 53(2):412-20. PubMed ID: 18710908
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.
Wang B; Lv Z; Zhang P; Su J
Medicine (Baltimore); 2018 Jun; 97(25):e11219. PubMed ID: 29924052
[TBL] [Abstract][Full Text] [Related]
9. Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.
Wang FD; Liao CH; Lin YT; Sheng WH; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):2041-52. PubMed ID: 24930042
[TBL] [Abstract][Full Text] [Related]
10. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
11. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Cheng JW; Liu C; Kudinha T; Xiao M; Fan X; Yang CX; Wei M; Liang GW; Shao DH; Xiong ZJ; Hou X; Yu SY; Wang Y; Yang QW; Su JR; Xu YC
Int J Antimicrob Agents; 2020 Jul; 56(1):105981. PubMed ID: 32330584
[TBL] [Abstract][Full Text] [Related]
12. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Ruiz J; Marco F; Sierra JM; Aguilar L; Garcia-Mendez E; Mensa J; Jiménez De Anta MT; Vila J
Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
15. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
16. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
Chen YB; Gu SL; Shen P; Lv T; Fang YH; Tang LL; Li LJ
J Med Microbiol; 2018 Jan; 67(1):52-59. PubMed ID: 29160203
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan.
Yamagishi Y; Nishiyama N; Koizumi Y; Matsukawa Y; Suematsu H; Hagihara M; Katsumata K; Mikamo H
J Infect Chemother; 2017 Oct; 23(10):724-726. PubMed ID: 28527649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
